ContextVision Crecimiento futuro
Future controles de criterios 3/6
Se prevé un crecimiento anual de los beneficios y los ingresos de ContextVision de 41.2% y 1.8% por año respectivamente. Se prevé que el BPA crezca en un 42.4% al año. Se espera que la rentabilidad financiera sea de 12.7% en 3 años.
Información clave
41.2%
Tasa de crecimiento de los beneficios
42.41%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Healthcare Services | 25.4% |
| Tasa de crecimiento de los ingresos | 1.8% |
| Rentabilidad financiera futura | 12.65% |
| Cobertura de analistas | Low |
| Última actualización | 25 Feb 2026 |
Actualizaciones recientes sobre el crecimiento futuro
Artículo de análisis • Nov 09
ContextVision AB (publ) (OB:CONTX) Just Reported, And Analysts Assigned A kr5.00 Price Target
It's been a mediocre week for ContextVision AB (publ) ( OB:CONTX ) shareholders, with the stock dropping 11% to kr3.84...Artículo de análisis • Aug 30
Earnings Release: Here's Why Analysts Cut Their ContextVision AB (publ) (OB:CONTX) Price Target To kr5.00
ContextVision AB (publ) ( OB:CONTX ) shareholders are probably feeling a little disappointed, since its shares fell...Recent updates
Actualización de narrativa • Apr 28
CONTX: Liver Biomarker Collaboration Will Sustain Overvaluation Risk For Ultrasound AI
Analysts have adjusted their price targets on ContextVision to reflect updated assumptions on revenue growth, profit margins and future P/E. The new target is now set at NOK X.XX, compared with the previous NOK Y.YY.Actualización de narrativa • Apr 12
CONTX: Liver Biomarker Collaboration Will Support Fair Outlook For Ultrasound AI
Analysts have adjusted their price target on ContextVision to reflect updated assumptions for the discount rate, revenue growth, profit margin and future P/E. The implied fair value estimate now stands at NOK 3.30.Actualización de narrativa • Mar 28
CONTX: Liver Study And Data Quality Program Will Support Fair Future Prospects
Analysts have adjusted their price target for ContextVision to align with a fair value estimate of NOK 3.30 per share, citing slightly updated assumptions for the discount rate and future P/E ratio, while keeping revenue growth and profit margin expectations broadly unchanged. Valuation Changes Fair Value: NOK 3.30 per share remains unchanged in the updated assessment.Actualización de narrativa • Mar 11
CONTX: Liver Study And Data Quality Program Will Support Balanced Future Prospects
Analysts have reduced their fair value estimate for ContextVision from NOK 4.0 to NOK 3.3, citing updated assumptions for revenue growth, profit margins, future P/E levels, and a slightly higher discount rate. Valuation Changes Fair Value: Reduced from NOK 4.0 to NOK 3.3 per share, a modest cut in the equity valuation used in the model.Actualización de narrativa • Feb 24
CONTX: Liver Study And Data Quality Program Will Support Stronger Future Upside
Analysts have raised their price target for ContextVision, citing slightly stronger assumptions on revenue growth, a marginally lower discount rate and a modestly higher future P/E. They have kept fair value and long-term profit margin expectations broadly in line with prior estimates, which together support a higher NOK-based valuation range.Actualización de narrativa • Feb 09
CONTX: Liver Diagnostics Study Progress Will Support Steady Long Term Outlook
Analysts have adjusted their price target for ContextVision to reflect a fair value of $4.00 and a future P/E of 11.34, citing updated assumptions around discount rates and profitability. What's in the News ContextVision started patient enrollment in its clinical development program for liver disease diagnostics at the University of Washington in Seattle, following Institutional Review Board approval and completion of technical setup (Key Developments).Actualización de narrativa • Jan 25
CONTX: Liver Study Progress And Buybacks Will Support Steady Long Term Outlook
Analysts have nudged their price target on ContextVision slightly higher to reflect small updates to fair value, discount rate, revenue growth, profit margin and future P/E assumptions, while keeping their overall outlook broadly unchanged. What's in the News ContextVision started the clinical phase of its liver disease diagnostics program at the University of Washington in Seattle, with the first patient first visit completed following Institutional Review Board approval and technical validation (Key Developments).Actualización de narrativa • Jan 10
CONTX: Share Buybacks And Stable Assumptions Will Support Steady Long Term Outlook
Analysts have slightly adjusted their price target on ContextVision, reflecting modest tweaks to fair value, discount rate, revenue growth, profit margin and future P/E assumptions. They describe the move as a fine tuning of their outlook rather than a major shift in thesis.Actualización de narrativa • Dec 25
CONTX: Share Buybacks Will Support Per Share Metrics With Stable Long Term Outlook
Analysts have nudged their price target on ContextVision slightly higher to reflect modest improvements in long term fair value and profitability assumptions, now estimating the stock to be worth approximately SEK 4.00 per share versus about SEK 4.00 previously. What's in the News Completed a share buyback tranche, repurchasing 1,440,211 shares (equivalent to 1.86% of outstanding capital) between September 5 and September 30, 2025 (Key Developments) Total consideration for the completed buyback program amounted to NOK 6.42 million under the mandate announced on September 15, 2025 (Key Developments) The conclusion of this buyback tranche reduces the free float and may provide incremental support to per share metrics ahead of future results updates (Key Developments) Valuation Changes Fair Value Estimate is effectively unchanged at around SEK 4.00 per share, reflecting only immaterial rounding differences in the model.Actualización de narrativa • Dec 11
CONTX: Share Buybacks Will Support Capital Efficiency With Balanced Long Term Outlook
Analysts have raised their price target for ContextVision slightly, now valuing the shares at roughly SEK 4.00. This reflects modestly higher confidence in the companys long term earnings power, even as underlying model assumptions have changed only marginally.Actualización de narrativa • Nov 27
CONTX: Share Repurchase Program Will Drive Capital Efficiency And Future Upside
Analysts have adjusted their price target for ContextVision slightly upward to $4.00, citing marginal updates to the discount rate as well as modest changes in growth and profitability assumptions. What's in the News ContextVision completed the repurchase of 1,440,211 shares, representing 1.86% of shares, for NOK 6.42 million between September 5 and September 30, 2025.Artículo de análisis • Nov 19
More Unpleasant Surprises Could Be In Store For ContextVision AB (publ)'s (OB:CONTX) Shares After Tumbling 25%
The ContextVision AB (publ) ( OB:CONTX ) share price has fared very poorly over the last month, falling by a...Actualización de narrativa • Nov 12
CONTX: Share Repurchase Program And Margin Outlook Will Shape Future Performance
Analysts have lowered their price target for ContextVision from $5.00 to $4.00, citing a modest decline in expected revenue growth and a slightly higher discount rate. This adjustment comes despite improved profit margin forecasts.Artículo de análisis • Nov 09
ContextVision AB (publ) (OB:CONTX) Just Reported, And Analysts Assigned A kr5.00 Price Target
It's been a mediocre week for ContextVision AB (publ) ( OB:CONTX ) shareholders, with the stock dropping 11% to kr3.84...Artículo de análisis • Sep 09
We Think That There Are More Issues For ContextVision (OB:CONTX) Than Just Sluggish Earnings
A lackluster earnings announcement from ContextVision AB (publ) ( OB:CONTX ) last week didn't sink the stock price...Artículo de análisis • Aug 30
Earnings Release: Here's Why Analysts Cut Their ContextVision AB (publ) (OB:CONTX) Price Target To kr5.00
ContextVision AB (publ) ( OB:CONTX ) shareholders are probably feeling a little disappointed, since its shares fell...Actualización de narrativa • Aug 09
Future Investments In POCUS And Asian Expansion Will Strengthen Market Presence
The downward revision in ContextVision's price target reflects a notable reduction in expected revenue growth, only partially offset by a modest improvement in profit margins, resulting in a lower fair value estimate of NOK5.00. What's in the News ContextVision entered a research partnership with AMRA Medical to advance AI-powered imaging solutions for metabolic dysfunction-associated steatotic liver disease (MASLD).Artículo de análisis • May 09
This Broker Just Slashed Their ContextVision AB (publ) (OB:CONTX) Earnings Forecasts
One thing we could say about the covering analyst on ContextVision AB (publ) ( OB:CONTX ) - they aren't optimistic...Artículo de análisis • Mar 04
There May Be Some Bright Spots In ContextVision's (OB:CONTX) Earnings
The market for ContextVision AB (publ)'s ( OB:CONTX ) shares didn't move much after it posted weak earnings recently...
Nueva narrativa • Feb 26
Future Investments In POCUS And Asian Expansion Will Strengthen Market Presence
Expansion into Asian markets and integration with new customers will boost revenues via enhanced customer base and market presence.Artículo de análisis • Feb 25
Subdued Growth No Barrier To ContextVision AB (publ) (OB:CONTX) With Shares Advancing 25%
ContextVision AB (publ) ( OB:CONTX ) shares have had a really impressive month, gaining 25% after a shaky period...Artículo de análisis • Feb 15
Is Now An Opportune Moment To Examine ContextVision AB (publ) (OB:CONTX)?
While ContextVision AB (publ) ( OB:CONTX ) might not have the largest market cap around , it saw a significant share...Artículo de análisis • Sep 02
There May Be Some Bright Spots In ContextVision's (OB:CONTX) Earnings
Shareholders appeared unconcerned with ContextVision AB (publ)'s ( OB:CONTX ) lackluster earnings report last week. Our...Artículo de análisis • Mar 11
ContextVision AB (publ)'s (OB:CONTX) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/ERatio
ContextVision AB (publ) ( OB:CONTX ) shares have had a horrible month, losing 26% after a relatively good period...Artículo de análisis • Feb 22
ContextVision's (OB:CONTX) Soft Earnings Are Actually Better Than They Appear
The most recent earnings report from ContextVision AB (publ) ( OB:CONTX ) was disappointing for shareholders. However...Artículo de análisis • Feb 18
ContextVision AB (publ) Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
It's been a mediocre week for ContextVision AB (publ) ( OB:CONTX ) shareholders, with the stock dropping 17% to kr7.50...Artículo de análisis • Jan 26
Earnings Not Telling The Story For ContextVision AB (publ) (OB:CONTX)
With a price-to-earnings (or "P/E") ratio of 18.4x ContextVision AB (publ) ( OB:CONTX ) may be sending very bearish...Artículo de análisis • Jun 22
When Should You Buy ContextVision AB (publ) (OB:CONTX)?
While ContextVision AB (publ) ( OB:CONTX ) might not be the most widely known stock at the moment, it saw a decent...Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2028 | 118 | 16 | 16 | 23 | 1 |
| 12/31/2027 | 116 | 12 | 12 | 19 | 1 |
| 12/31/2026 | 113 | 8 | 10 | 16 | 1 |
| 3/31/2026 | 113 | 5 | 5 | 8 | N/A |
| 12/31/2025 | 111 | 1 | 0 | 4 | N/A |
| 9/30/2025 | 109 | 4 | 2 | 9 | N/A |
| 6/30/2025 | 116 | 9 | 6 | 14 | N/A |
| 3/31/2025 | 120 | 13 | 19 | 26 | N/A |
| 12/31/2024 | 131 | 25 | 29 | 33 | N/A |
| 9/30/2024 | 135 | 22 | 30 | 30 | N/A |
| 6/30/2024 | 138 | 26 | 35 | 36 | N/A |
| 3/31/2024 | 138 | 33 | 42 | 43 | N/A |
| 12/31/2023 | 133 | 33 | 44 | 45 | N/A |
| 9/30/2023 | 135 | 37 | 40 | 44 | N/A |
| 6/30/2023 | 130 | 36 | 40 | 43 | N/A |
| 3/31/2023 | 128 | 36 | 36 | 40 | N/A |
| 12/31/2022 | 123 | 33 | 21 | 26 | N/A |
| 9/30/2022 | 117 | 34 | 18 | 25 | N/A |
| 6/30/2022 | 115 | 37 | 9 | 15 | N/A |
| 3/31/2022 | 106 | 35 | -4 | 2 | N/A |
| 12/31/2021 | 100 | 35 | 5 | 9 | N/A |
| 9/30/2021 | 94 | 53 | 8 | 8 | N/A |
| 6/30/2021 | 90 | 42 | 10 | 11 | N/A |
| 3/31/2021 | 86 | 35 | 18 | 23 | N/A |
| 12/31/2020 | 95 | 38 | 14 | 22 | N/A |
| 9/30/2020 | 99 | 8 | 11 | 23 | N/A |
| 6/30/2020 | 100 | 10 | 9 | 26 | N/A |
| 3/31/2020 | 103 | 13 | 0 | 20 | N/A |
| 12/31/2019 | 95 | 7 | N/A | 25 | N/A |
| 9/30/2019 | 95 | 14 | N/A | 22 | N/A |
| 6/30/2019 | 94 | 11 | N/A | 24 | N/A |
| 3/31/2019 | 93 | 5 | N/A | 11 | N/A |
| 12/31/2018 | 91 | -1 | N/A | 5 | N/A |
| 9/30/2018 | 85 | -2 | N/A | 5 | N/A |
| 6/30/2018 | 82 | -3 | N/A | 5 | N/A |
| 3/31/2018 | 82 | -2 | N/A | 4 | N/A |
| 12/31/2017 | 81 | -2 | N/A | 2 | N/A |
| 9/30/2017 | 83 | -1 | N/A | 5 | N/A |
| 6/30/2017 | 85 | 1 | N/A | 1 | N/A |
| 3/31/2017 | 81 | 0 | N/A | 4 | N/A |
| 12/31/2016 | 82 | 4 | N/A | 10 | N/A |
| 9/30/2016 | 76 | 3 | N/A | 6 | N/A |
| 6/30/2016 | 73 | 4 | N/A | 10 | N/A |
| 3/31/2016 | 72 | 5 | N/A | 12 | N/A |
| 12/31/2015 | 72 | 5 | N/A | 9 | N/A |
| 9/30/2015 | 70 | 5 | N/A | 9 | N/A |
| 6/30/2015 | 67 | 4 | N/A | 10 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (41.2% al año) de CONTX es superior a la tasa de ahorro (3.3%).
Beneficios vs. Mercado: Se prevé que los beneficios (41.2% al año) de CONTX crezcan más rápidamente que el mercado Norwegian (9.5% al año).
Beneficios de alto crecimiento: Se espera que los beneficios de CONTX crezcan significativamente en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que los ingresos (1.8% al año) de CONTX crezcan más despacio que el mercado de Norwegian (2.1% al año).
Ingresos de alto crecimiento: Se prevé que los ingresos 1.8% al año) de CONTX crezcan más despacio que 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Se prevé que la rentabilidad financiera de CONTX sea baja dentro de 3 años (12.7%).
Descubre empresas en crecimiento
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/21 14:51 |
| Precio de las acciones al final del día | 2026/05/21 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
ContextVision AB (publ) está cubierta por 3 analistas. 1 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Juste Subataviciute | Norne Securities AS |
| Christian Lee | Pareto Securities |
| Klas Palin | Redeye |